Paper Review Records
All Paper Review Records
16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
CD74 links MHC class II risk to tumor immune microenvironment remodeling across the Sjögren-to-lymphoma axis
Shuyuan Liu; Meng Li; Yingying Wang; Xinhao Xia; Peiying Wang; Zhijie Ni; Qingyun Li; Qifei Teng; Wenlin Han; Jiani Liu; Xiaodong Wang; Sheng Yu; Hui Zhang; Xiangxin Meng; Fei Zhong; Hao WangShow moreShow less
The Affiliated Guangzhou Hospital of TCM of Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong, China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China; Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, China; Department of Traditional Chinese Internal Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong, ChinaShow moreShow less
MF1, a novel robustic acid derivative, exerts antitumor effects in hepatocellular carcinoma
Juanjuan Huang; Lijuan Teng; Tianxiu Meng; Yuqiong Liang; Yaoqi Li; Jinyan LvShow moreShow less
Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, 530004, China; Krirk University, Bangkhen, Bangkok, 10220, Thailand; School of Public Health, Yale University, New Haven, CT, 06510, USAShow moreShow less
The CARM1–YIPF2 axis drives breast cancer progression and predicts poor prognosis
Xitao Gao; Shuchang Zhang; Wei Peng; Kun XuShow moreShow less
Department of Breast Surgery, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Breast Surgery, The Affiliated Hospital of Kangda College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Breast Surgery, Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, 42 Baiziting, Nanjing, 210009, China; Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing, 210009, ChinaShow moreShow less
Aggressive features and immune landscape of macrotrabecular hepatocellular carcinoma
Lixia Wu; Meidan Li; Xuefang Wang; Qionglan Wu; Yi Chen; Bin Wang; Lihong ChenShow moreShow less
Department of Pathology, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, 350025, China; Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350004, ChinaShow moreShow less
A renal cyst-clear cell renal cell carcinoma comorbidity analysis identifies a FOXM1-positive epithelial COL6A1-CD44 axis that remodels fibroblasts
Hao Lv; Chenyi Ge; Yuming Jin; Yu Fang; Wenqiang Liu; Yan Zhang; Hanzhong Zhang; Chencan Fang; Le Qu; Xin Lu; Wentao Zhang; Nan Zhang; Aimin Jiang; Lingfeng Wu; Linhui WangShow moreShow less
Department of Urology, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China; Department of Urology, The First Naval Hospital of Southern Theater Command, Zhanjiang, China; Department of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China; Department of Urology, Henan Corps Hospital of Chinese People's Armed Police Force, Zhengzhou, Henan, China; Department of Urology, The Frist Hospital of Jiaxing, Frist Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, ChinaShow moreShow less
Shared inflammatory-metabolic transcriptional effects in tubulointerstitial fibrosis and clear cell renal cell carcinoma
Sha Tang; Furong Li; Ling Nie; Yinghui Huang; Yiqin Wang; Jinghong Zhao; Yan LiShow moreShow less
Department of Nephrology, the Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, PR ChinaShow moreShow less
FAQ
How long does Translational Oncology take to review a manuscript?
As of 2026-11-19, CrushSCI has 16 complete review records for Translational Oncology. The fastest paper went from submission to acceptance in 60 days (A renal cyst-clear cell renal cell carcinoma comorbidity analysis identifies a FOXM1-positive epithelial COL6A1-CD44 axis that remodels fibroblasts, received 2026-07-27, accepted 2026-09-25); the slowest took 538 days. The average is 123.6 days and the median is 97 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
